Document is current

Documents that mention this clinical trial

Efficacy and Safety of Linagliptin in Subjects With Long-standing Type 2 Diabetes Mellitus (>10 Years): Evidence From Pooled Data of Randomized, Double-blind, Placebo-controlled, Phase III Trials
https://doi.org/10.1016/j.clinthera.2014.07.020

Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies
https://doi.org/10.1016/j.clinthera.2014.06.008

Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial ^(Results)
https://doi.org/10.2337/dc19-0783

Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy
https://doi.org/10.1016/s0140-6736(14)61402-1

Nonglycemic Outcomes of Antidiabetic Medications
https://doi.org/10.2337/cd18-0015

Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial ^(Results)
https://doi.org/10.2337/dc20-0279

DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials
https://doi.org/10.2337/dc20-2018

Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
https://doi.org/10.2337/dc15-2237

Kidney Disease End Points in a Pooled Analysis of Individual Patient–Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes
https://doi.org/10.1053/j.ajkd.2015.03.024

Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial
https://doi.org/10.2337/dc14-2868

An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors
https://doi.org/10.1080/14740338.2019.1626823

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
https://doi.org/10.1186/s12933-018-0682-3

Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials
https://doi.org/10.1136/bmjdrc-2014-000020

SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management
https://doi.org/10.2337/dc18-0588

Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?
https://doi.org/10.2337/dc17-0068